---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-100902"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:26:00.536116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MindMed Q2 2025 net loss widens to $42.7M; cash $237.9M; Phase 3 trials on track

## Summary
- Net loss of $42.7M in Q2 2025 vs $5.9M in Q2 2024, driven by higher R&D and warrant fair value changes.
- Cash, cash equivalents and investments totaled $237.9M as of June 30, 2025, sufficient into 2027.
- R&D expenses rose to $29.8M from $14.6M YoY, primarily due to MM120 ODT program advancement.
- Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) and Emerge (MDD) data in 2H 2026.
- Appointed Brandi L. Roberts as CFO, bringing over 25 years of life sciences financial leadership.

## SEC filing metadata
- accession: 0000950170-25-100902
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/0000950170-25-100902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-100902
- JSON: https://secwatch.observer/filing/0000950170-25-100902.json
- Plain text: https://secwatch.observer/filing/0000950170-25-100902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.